Chart — Pharmacology
Insulin Administration Chart
Administration workflow for all insulin types — timing relative to meals, storage requirements, mixing compatibility, appearance verification, and safety checklist steps.
Educational use only. Insulin is a high-alert medication. All insulin administration requires a provider order and an independent two-nurse verification per institutional policy. Check blood glucose before every insulin dose. This material supports nursing education and exam review. It is not medical advice and is not a substitute for clinical judgment, institutional policy, or medical direction. Always follow facility protocols and current provider orders.
Administration Workflow by Insulin Type
| Insulin Type | Meal Timing | Key Workflow Steps | NPO / Meal Held |
|---|---|---|---|
| Rapid-Acting (Lispro, Aspart, Glulisine) | |||
| Rapid-acting | 0–15 min before meal; some protocols allow immediately after meal if intake confirmed |
| Hold and notify provider. Never give rapid-acting insulin without a meal unless provider orders it for correction. |
| Short-Acting — Regular Insulin (Humulin R / Novolin R) | |||
| Regular (SubQ) | 30 min before meal |
| Hold and notify provider. Coordinate carefully with dietary — 30-min window is strict. |
| Regular (IV) | Continuous infusion or intermittent IV per protocol (DKA, HHS, perioperative) |
| IV Regular is used specifically during NPO/critical illness periods — NPO is not a contraindication for IV infusion. |
| Intermediate-Acting — NPH (Humulin N / Novolin N) | |||
| NPH | Not meal-dependent; typically given before breakfast ± bedtime per provider order |
| Verify with provider — may reduce dose or hold depending on clinical status. |
| Long-Acting — Glargine, Detemir (Basal) | |||
| Glargine (Lantus, Basaglar) | Not meal-dependent; once daily at the same time each day |
| Typically continued at reduced dose per provider order — verify. Basal coverage is maintained even during NPO. |
| Detemir (Levemir) | Not meal-dependent; once or twice daily at consistent times | Same as glargine: label verification, two-nurse check, no mixing, site rotation | Verify with provider — typically continued at reduced dose. |
| Ultra Long-Acting — Degludec (Tresiba) | |||
| Degludec (Tresiba) | Not meal-dependent; once daily — flexible ±8 hr window acceptable | Same as glargine, with one safety note: the Tresiba U-200 pen requires NO dose conversion — the dose counter shows the actual units delivered (do not double the dialed number) | Typically continued — verify with provider. Flexible timing window especially useful during variable schedules. |
Insulin Storage Requirements
| Status | Storage | Beyond-Use Period | Notes |
|---|---|---|---|
| Unopened vials / pens | Refrigerated (36–46°F / 2–8°C); do not freeze | Until labeled expiration date | Do not use if frozen or exposed to direct sunlight for extended periods |
| Opened vials (most types) | Room temperature (below 77°F / 25°C) or refrigerated | 28–30 days after opening (varies by product) | Date vial when opened; discard per manufacturer guidance regardless of remaining volume |
| Opened insulin pens | Room temperature (below 77°F / 25°C) | 14–56 days depending on product (check labeling) | Do NOT refrigerate in-use pens — cold insulin increases injection discomfort; condensation can affect dosing |
| IV Regular insulin infusion | Per pharmacy preparation guidelines | Per institutional policy (typically 24–48 hr) | Insulin adsorbs to IV tubing — prime tubing per protocol before connecting to patient |
Always verify beyond-use periods against current manufacturer prescribing information — values vary across products.
Pre-Administration Appearance Verification
| Expected Appearance | Applies To | If Appearance Differs |
|---|---|---|
| Clear solution | Rapid-acting, Regular, Glargine, Detemir, Degludec | Discard — cloudy, discolored, or particulate clear insulins are degraded and must not be used |
| Cloudy white suspension | NPH; premixed insulins (70/30) | Roll gently to resuspend — particles should disperse evenly. Discard if flocculent, clumped, or particles do not resuspend |
Critical safety point: Glargine (Lantus) and Regular (Humulin R) are both clear and look identical in a vial. Read the label before every preparation — do not rely on appearance alone to distinguish these insulins.
Mixing Workflow — Regular + NPH
Rule: “Clear before cloudy” — draw Regular first, then NPH
- Inject air into the NPH (cloudy) vial equal to the NPH dose — do not withdraw insulin
- Withdraw needle from NPH vial
- Inject air into the Regular (clear) vial equal to the Regular dose
- Invert Regular vial and withdraw the prescribed Regular dose
- Insert needle into NPH vial and withdraw the prescribed NPH dose
- Administer immediately — do not let mixed insulin sit in the syringe
Rationale: If NPH is drawn first and accidentally pushed back into the Regular vial, it contaminates Regular insulin and slows its onset unpredictably. Drawing Regular first prevents this.
Long-acting insulins (glargine, detemir, degludec) — NEVER mix
These require a separate injection in a separate site. Mixing alters the pH and pharmacokinetics — absorption becomes unpredictable.
Pre-Administration Safety Checklist
Related Resources
Standards & sources
Fact-checked Jun 20, 2026This page is written to align with ADA / FDA Prescribing Data. It is an educational summary, not a citation of any single document — always verify specific doses, values, and protocols against current guidelines and your facility policy. How we source content →